MannKind Corp (NAS:MNKD)
$ 4.41 0.09 (2.08%) Market Cap: 1.20 Bil Enterprise Value: 1.14 Bil PE Ratio: 110.25 PB Ratio: 0 GF Score: 76/100

MannKind Corp at RBC Capital Markets Global Healthcare Conference Transcript

May 17, 2022 / 03:00PM GMT
Release Date Price: $3.36 (+9.80%)
Greg Renza
RBC Capital Markets - Analyst

(technical difficulty) back to the 2022 RBC Global Healthcare Conference. My name is Greg Renza, one of the senior biotechnology equity research analysts here at RBC. And we're pleased to be joined by MannKind today. And joining us is the CEO, Michael Castagna. Michael, thanks so much for joining us. Great to see you and be in person.

Michael Castagna
MannKind Corporation - CEO

Great to meet you in person.

Questions & Answers

Greg Renza;Michael Castagna<
RBC Capital Markets - Analyst

Yes, it's the first time, and a lot of virtual, but now is the time to get back to some degree of normalcy. And with that, for those of us who aren't familiar with MannKind, maybe, Mike, we can just start with having you give us a brief introduction to the Company. But also, I think particularly relevant is an announcement today on a deal that you and the team have conducted, so that maybe we could also hear a little bit about that and what you took in this morning.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot